Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.02.
Forward PE Ratio (17.02) = Close Price ($211.00) / Consensus Forward EPS ($12.49)
FORWARD PE RATIO
17.02
SECTOR MEDIAN · HEALTHCARE
19.84
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-14.19%
vs the sector median at left
Biogen Inc.
Market Cap
$31.18B
Forward PE Ratio
17.02
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Biogen Inc. (BIIB) | $31.18B | 17.02 |
| Zoetis Inc. (ZTS)vs › | $30.75B | 11.76 |
| Centene Corp. (CNC)vs › | $31.72B | 13.45 |
| Waters Corporation (WAT)vs › | $30.56B | 27.65 |
| ResMed Inc. (RMD)vs › | $31.92B | 19.87 |
| DexCom, Inc. (DXCM)vs › | $32.00B | 31.69 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.99B | 13.56 |
| Medline Inc. (MDLN)vs › | $29.52B | 23.24 |
| Alcon Inc. (ALC)vs › | $33.61B | 19.80 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.25B | 38.72 |
Trailing P/E
37.6
reported TTM EPS
Forward P/E
17.0
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.49 implies +121.1% EPS growth vs the reported trailing $5.65.
At today's $211.00 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $12.49 | $10.72 – $15.30 | 19 | 16.9x |
| 2027-12-31 | $16.55 | $11.60 – $19.82 | 19 | 12.7x |
| 2028-12-31 | $18.68 | $13.53 – $25.38 | 9 | 11.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute